•  
  •  
 

Abstract

Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade.

Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability.

Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.

DOI

10.55729/2000-9666.1659

Share

COinS